Illumina, Inc.
Illumina Reports Q4 and FY 2024 Financial Results
Summary
Illumina, Inc. reported its financial results for the fourth quarter and fiscal year 2024. The company achieved core revenue of $1.1 billion for Q4 2024, up 1% from Q4 2023, and $4.3 billion for FY 2024, down 2% from FY 2023. GAAP operating margin for Q4 2024 was 15.8%, and non-GAAP operating margin was 19.7%. GAAP diluted EPS for Q4 2024 was $0.73, and non-GAAP diluted EPS was $0.95. For fiscal year 2025, the company expects core revenue growth in the low single digits and a non-GAAP operating margin of approximately 23%.
Profitelligence Alerts
Get alerts for ILMN
Be first to know when Illumina, Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Illumina, Inc.
Illumina, Inc. operates as a global leader in the life sciences industry, focusing on the development and manufacturing of integrated systems for the analysis of genetic variation and function. Primarily, Illumina’s products and services are pivotal in advancing genomic research, enabling scientists to explore DNA sequencing and genetic mapping with high precision and efficiency. The company’s solutions are extensively utilized in fields such as oncology, reproductive health, and genetic disease diagnostics. Known for its cutting-edge sequencing tools, Illumina plays a crucial role in driving innovation in personalized medicine, helping to tailor medical treatments to individual genetic profiles. Headquartered in San Diego, California, Illumina contributes significantly to the genomics sector’s expansion, supporting initiatives in health and medicine, agrigenomics, and microbiology. By providing critical tools for genetic analysis, Illumina aids researchers and clinical laboratories worldwide, influencing how healthcare is approached and offering insights into complex biological systems.
Official SEC Documents
Advertisement